In accordance with 35 USC § 287(a), Takeda provides United States Patent information concerning its products on this website. Also, in accordance with section 123 of the Australian Patents Act, Takeda provides Australian Patent information concerning its products on this website. For each of the products listed below, the product is patented under, made under, or used under one or more of the patents listed with the product name.
The patent information displayed on this page is believed to be accurate as of the most recent update of the page, but should not be considered exhaustive. In particular, the omission of a particular patent from a product’s entry on this page is not a representation or admission by Takeda that that patent does not cover the product; nor does the absence of any listing on this page for a specific Takeda product constitute a representation or admission by Takeda that that product is unpatented. In addition, although Takeda has attempted to keep the information on this page reasonably current, certain patents listed on this page may have expired since the page was last updated.
Please note that some of the products marketed below were sold under the name of Shire plc, and its subsidiaries. These products may be marketed currently by Takeda with labeling that references a subsidiary of Shire plc as the manufacturer and/or distributor, and that reference the patent-marking webpage www.shire.com/legal-notice/product-patents or www.baxalta.com/productpatents/ .
Please find the product name below to view associated United States Patents.
ADVATE® (Antihemophilic Factor [Recombinant]) and BAXJECT III® Reconstitution System
Patented under and/or made under U.S. Patent Numbers: 6,586,573, 7,087,723, 8,058,226, 8,372,800, and 8,545,476.
ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] and BAXJECT III® Reconstitution System
Patented under U.S. Patent Numbers: 6,586,573, 7,087,723, 7,199,223, 8,058,226, 8,133,977, 8,143,378, 8,247,536, 8,372,800, and 8,545,476.
GATTEX® (teduglutide [rDNA origin]) for Injection
Patented under and/or used under U.S. Patent Numbers: 5,789,379, 7,056,886, 7,847,061, 9,060,992, 9,539,310, 9,545,434, 9,545,435, 9,555,079, 9,572,867, 9,592,273, 9,592,274, 9,968,655, 9,968,656, 9,968,658, 9,974,835, 9,974,837, 9,981,014, 9,981,016, 9,987,334, 9,987,335, and 9,993,528.
HYQVIA® (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase)
Patented under U.S. Patent Number 7,767,429, under license from Halozyme, Inc., a wholly owned subsidiary of Halozyme Therapeutics, Inc.
MYDAYIS® (Mixed Salts of a Single-entity Amphetamine Product)
Patented under and/or used under U.S. Patent Numbers: RE 41148, RE 42096, 6,913,768, 8,846,100 and 9,173,857.
VIPRIV® (velaglucerase alfa for injection)
Patented under, used under, and/or made under U.S. Patent Numbers: 7,138,262, 7,833,766, 9,072,785, 9,694,057, and 10,041,137.
VONVENDI® [von Willebrand factor (Recombinant)]
Patented under and/or used under U.S. Patent Numbers: 6,465,624, 6,531,577, 6,579,723, 8,058,411 and 8,597,910.
Patented under, used under, and/or made under U.S. Patent Numbers 8,822,653, 8,816,055 and 9,266,964.
XIIDRA® (Lifitegrast Ophthalmic Solution) 5%
Patented under, used under, and/or made under U.S. Patent Numbers: 7,314,938, 7,745,460, 7,790,743, 7,928,122, 8,084,047, 8,168,655, 8,367,701, 8,592,450, 8,927,574, 9,085,553, 9,216,174, 9,353,088 and 9,447,077.
Patented under, and/or used under, Australian Patent Numbers: 2004287875, 2006247136, and 2008317473.